Leptomeningeal metastasis is an uncommon and typically late complication of cancer with a
poor prognosis and limited treatment options. Diagnosis is often challenging, with …

Leptomeningeal carcinomatosis occurs in approximately 5% of patients with cancer. This
disorder is being diagnosed with increasing frequency as patients live longer and as neuro …

These EANO–ESMO joint recommendations for the diagnosis and treatment of
leptomeningeal metastasis (LM) from solid cancers represent the first European guideline …

Leptomeningeal metastasis (LM) results from metastatic spread of cancer to the
leptomeninges, giving rise to central nervous system dysfunction. Breast cancer, lung …

Leptomeningeal disease has become increasingly prevalent as novel therapeutic
interventions extend the survival of cancer patients. Although a majority of leptomeningeal …

Purpose This review assesses the current state of knowledge regarding preclinical and
clinical pharmacology for brain tumor chemotherapy and evaluates relevant brain tumor …

Abstract The term “neurolymphomatosis”(NL) has included infiltration of the peripheral
nervous system by lymphoma and nontumor lymphocytes. We describe NL as a lymphoma …

Leptomeningeal metastasis occurs in~ 5% of all patients with cancer and is the third most
common metastatic complication of the central nervous system. Staging of leptomeningeal …

Leptomeningeal metastasis (LM), ie the seeding of tumor cells to the cerebrospinal fluid
(CSF) and the leptomeninges, is a devastating and mostly late-stage complication of various …

Neoplastic meningitis is a complication of the CNS that occurs in 3–5% of patients with
cancer and is characterised by multifocal neurological signs and symptoms. Diagnosis is …